However, hepatic SFRP5 could have a protective role in the first steps of NAFLD in an attempt to inhibit the noncanonical WNT pathway but could be deregulated at the advanced stage of the disease while WNT5A and JNK are activated, thus promoting liver damage. This evidence concerns the gene SFRP5 and metabolic dysfunction-associated steatotic liver disease.